Chrysos Corporation reports a robust Q2 FY25 with a 12% quarter-on-quarter and 53% year-on-year revenue increase, driven by expanding international sales and rising sample volumes. The company secured two new contracts, boosting its PhotonAssay™ footprint and maintaining strong financial health.
PolyNovo Limited reports a robust 22.8% revenue increase in 1H FY25, driven by strong U.S. and international sales growth and progressing FDA approval efforts for its NovoSorb platform.
